In the Era of Personalized Treatment and Targeted Therapies

In this MEDtalk Dr. Sergio Giralt presents the latest advances in AML therapy, with a spotlight on the exciting data set to be showcased at ASH2023. Discover the intricate challenges of treating FLT3 mutated AML, the critical role of stem cell transplantation across diverse patient groups, and the emergence of trailblazing conditioning regimens. Finally, Dr. Giralt celebrates the FDA approval of a transformative gene-edited therapy for sickle cell disease.